Kallyope Rebranded as TriGemX Bio Following $94 Million Raise

The biotech firm has secured fresh funding to advance its lead migraine treatment into Phase III clinical trials.

Updated on Oct. 1, 2026 in Biotech

Isometric editorial illustration of a three-dimensional anatomical nerve structure model resting on a clean geometric platform. — TriGemX Bio, formerly Kallyope, has secured $94 million in new financing to advance its oral migraine drug, elismetrep, into Phase III clinical trials. AI Illustration. Upload story photo >

Live Poll

Do you support pharmaceutical firms shifting investment from metabolic disease treatments toward new neurological drugs?

TriGemX Bio, formerly known as Kallyope, has raised $94 million to push its oral migraine drug, elismetrep, into late-stage testing. The company transitioned its focus from metabolic diseases to neurology following underwhelming obesity program results reported earlier this year.

Why it matters

The rebranding highlights a major strategic pivot for the company, which moved away from obesity research after selling three metabolic programs to Novo Nordisk. TriGemX Bio is now centering its clinical pipeline on the trigeminal ganglion, a key neural structure involved in the development of migraine pain.

The firm is utilizing a liquid-filled soft-gel formulation designed to improve rapid drug absorption. In its Phase IIb study, the 20 mg dose also achieved a 58.8% pain relief rate and 38.3% freedom from the most bothersome symptom.

The players

TriGemX Bio

Formerly known as Kallyope, this biotechnology firm focuses on developing therapies targeting neural pathways.

Novo Nordisk

This global healthcare company acquired three obesity-focused programs from the firm during its recent strategic pivot.

The Column Group

This venture capital firm specializes in early-stage life sciences investments and co-led the most recent financing round.

TCGX

This investment group focuses on the healthcare sector and participated as a co-lead in the recent funding effort.

Viking Global Investors

This global investment management firm served as a co-lead for the $94 million capital injection.

The details

Co-led by The Column Group, TCGX, and Viking Global Investors, the $94 million financing round will fund the advancement of the TRPM8 channel blocker elismetrep. This move follows a period of corporate reorganization after the company divested its obesity assets to Novo Nordisk in early 2025.

Early 2025: Company reported disappointing obesity data.
April 2026: Company announced improved soft-gel formulation for the drug.
October 1, 2026: Company announced rebranding and new financing.
October 2026: Expected start of second pivotal trial.
Mid-2027: Anticipated results from the first Phase III trial.

The Tech Race

The development of elismetrep signals a competitive shift toward non-triptan oral therapies that target the TRPM8 ion channel research landscape. By prioritizing neurology over metabolic research, the firm is positioning itself to challenge current standards in migraine symptom management.

Patients suffering from migraine may eventually benefit from an oral drug designed for rapid absorption via a liquid-filled soft-gel format. If successful in Phase III, this treatment could provide an alternative therapy option compared to current standard-of-care medications.

The takeaway

The firm transition underscores how biotech companies leverage clinical data to pivot between therapeutic categories. Investors and patients should monitor the upcoming 2027 trial results to gauge the long-term viability of this new neurological drug class.